Trius Therapeutics, Inc. (TSRX) Posts Better than Expected Q1 Results

Trius Therapeutics, Inc. (NASDAQ: TSRX) reported Q1 EPS of ($0.22), $0.12 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $9.83 million versus the consensus estimate of $5.38 million.

For earnings history and earnings-related data on Trius Therapeutics, Inc. (TSRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Brinker Int'l (EAT) PT Raised to $285 at UBS Following 'Impressive' Q4 Outperformance